Tandem Diabetes Care (TNDM) Projected to Post Quarterly Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) will likely be issuing its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.31) per share and revenue of $235.80 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Wednesday, August 6th. The medical device company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.08). The firm had revenue of $240.68 million for the quarter, compared to analysts’ expectations of $238.39 million. Tandem Diabetes Care had a negative net margin of 20.51% and a negative return on equity of 65.40%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.47) EPS. On average, analysts expect Tandem Diabetes Care to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tandem Diabetes Care Stock Performance

Shares of TNDM opened at $15.21 on Wednesday. Tandem Diabetes Care has a 1 year low of $9.98 and a 1 year high of $38.28. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44. The company’s 50 day simple moving average is $13.53 and its 200 day simple moving average is $16.23. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -4.92 and a beta of 1.51.

Analyst Upgrades and Downgrades

TNDM has been the subject of several research analyst reports. UBS Group dropped their price target on shares of Tandem Diabetes Care from $20.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, August 7th. Royal Bank Of Canada dropped their price target on shares of Tandem Diabetes Care from $45.00 to $25.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Lake Street Capital lowered shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating and dropped their price target for the stock from $75.00 to $12.00 in a research report on Monday, August 11th. Wells Fargo & Company dropped their price target on shares of Tandem Diabetes Care from $20.00 to $13.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Finally, Barclays dropped their price target on shares of Tandem Diabetes Care from $53.00 to $51.00 and set an “overweight” rating for the company in a research report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $21.19.

Insider Buying and Selling at Tandem Diabetes Care

In other Tandem Diabetes Care news, CFO Leigh Vosseller acquired 13,720 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $10.89 per share, with a total value of $149,410.80. Following the completion of the transaction, the chief financial officer directly owned 25,580 shares of the company’s stock, valued at approximately $278,566.20. The trade was a 115.68% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John F. Sheridan acquired 10,000 shares of the company’s stock in a transaction dated Monday, August 11th. The stock was acquired at an average cost of $10.23 per share, with a total value of $102,300.00. Following the transaction, the chief executive officer directly owned 106,327 shares of the company’s stock, valued at approximately $1,087,725.21. This represents a 10.38% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tandem Diabetes Care

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its stake in shares of Tandem Diabetes Care by 218.6% in the second quarter. Tower Research Capital LLC TRC now owns 9,168 shares of the medical device company’s stock valued at $171,000 after purchasing an additional 6,290 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Tandem Diabetes Care in the first quarter valued at $225,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Tandem Diabetes Care in the second quarter valued at $231,000. State of Wyoming boosted its stake in shares of Tandem Diabetes Care by 379.9% in the second quarter. State of Wyoming now owns 21,436 shares of the medical device company’s stock valued at $400,000 after purchasing an additional 16,969 shares during the period. Finally, Corient Private Wealth LLC boosted its stake in shares of Tandem Diabetes Care by 109.4% in the second quarter. Corient Private Wealth LLC now owns 23,600 shares of the medical device company’s stock valued at $440,000 after purchasing an additional 12,331 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.